# Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

> **NCT03934372** · PHASE1,PHASE2 · RECRUITING · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 70 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Accelerated Phase Chronic Myeloid Leukemia
- Blast Phase Chronic Myeloid Leukemia
- Chronic Phase Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- Leukemia
- Lymphoma
- Solid Tumors

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT03934372
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-29
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934372, "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03934372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*